Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This 76-week, 3-part Phase 1b/2 study is intended to evaluate the pharmacological properties
(pharmacokinetics and pharmacodynamics), safety, tolerability and preliminary effectiveness
of TOFA administrated to young adults (18-45 years) with moderately to severely active
SLE-CL. Subjects will be studied at the Cincinnati Children's Hospital Medical Center (CCHMC)
and in Cleveland at MetroHealth Medical Center.